When most of the companies in the pharmaceutical and other related fields are struggling to sustain their profitability, PDL BioPharma Inc (NASDAQ:PDLI) has ended another quarter and year on a high note. As per the reports, it announced financial results for the recently concluded the year 2015. The yearly revenue figure surpassed $590.4 million figure.
Insights of Financial Data
In 2014, PDL’s total revenues were $581 million. Given that the market hasn’t reacted favorably for most of the time, this growth in revenues from $581 million to $590 million is appreciable. Out of 2015’s total revenues, $485.2 million belonged to royalty received as license fees. PDL deals in many products; however, increased income in the year 2015 was driven mainly by the sales of Xolair, Perjeta, and Kadcyla.
When it comes to fourth quarter results, PDL’s revenues increased to $178.1 million as compared to $117.1 million in 4Q2014. Out of the total revenue figure, license fees covered a significant portion with $121.2 million. The estimated fair value of PDL’s primary royalty rights asset Depomed, Inc., increased during the fourth quarter, which affected the overall revenue position in a positive way.
Operating expenses for the year were $40.1 million as compared to $34.9 million in 2014. When it comes to net income for the year, PDL reported a whopping figure of $332.8 million or $2.03 per share as compared to net income of $332.2 million or $1.86 per share in 2014. Net income in 4Q2015 was $100.6 million against $55.1 million during the same period in 2014.
PDL generated total cash of $301.5 million from operating activities in 2015 as compared to $292.3 million during the same period in the year 2014. Despite all the excellent income and revenue figures, PDL’s cash and cash equivalent were $220.4 million at the end of 2015, compared to $293.7 million at the end of December 2014.
Going forward, it will look forward to taking many initiatives to attain profitable situation, details of which will be announced in the near future.
